WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
pttg near5 (carboxy or c) adj terminal	1

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L2

Refine Search | Recall Text | Clear

Search History

DATE: Wednesday, October 16, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB; PLUR=YES; OP=AND			
L2	pttg near5 (carboxy or c) adj terminal	1	L2
L1	pttg-c	1	L1

END OF SEARCH HISTORY

WEST

End of Result Set

☐ Generate Collection Print

L1: Entry 1 of 1 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147162
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147162 A1

TITLE: Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (PTTG)

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Heaney, Anthony P.	Los Angeles	CA	US	
Ishikawa, Hiroki	Nagasaki	CA	JP	
Yu, Run	Los Angeles	CA	US	
Horwitz, Gregory A.	Los Angeles	MA	US	
Zhang, Xun	Malden	CA	US	
Melmed, Shlomo	Los Angeles		US	

APPL-NO: 09/ 777422 [PALM]
DATE FILED: February 5, 2001

RELATED-US-APPL-DATA:
Application 09/777422 is a continuation-in-part-of US application 09/730469, filed December 4, 2000, PENDING
Application 09/730469 is a continuation-in-part-of US application 09/687911, filed October 13, 2000, PENDING
Application 09/687911 is a continuation-in-part-of US application 09/569956, filed May 12, 2000, PENDING
Application 09/569956 is a continuation-in-part-of US application 08/894251, filed July 23, 1999, PENDING
Application 08/894251 is a a-371-of-international WO application PC/T/US97/21463, filed November 21, 1997, UNKNOWN
Application is a non-provisional-of-provisional application 60/031338, filed November 21, 1996,

INT-CL: [07] A61 K 31/70, A01 N 43/04

US-CL-PUBLISHED: 514/44
US-CL-CURRENT: 514/44

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

Disclosed is a method of modulating angiogenesis in a tissue comprising mammalian cells, including cells of human origin, in vitro or in vivo. Also disclosed are a method of enhancing wound healing and/or tissue regeneration and a method of limiting scar formation.

[0001] This application is a continuation-in-part of U.S. Ser. No. 09/730,469, filed Dec. 4, 2000, which is a continuation-in-part of U.S. Ser. No.09/687,911, filed on Oct. 13, 2000, which is a continuation-in-part of U.S. Ser. No.09/569,956, filed on May 12, 2000, which is a continuation-in-part of U.S. Ser. No. 08/894,251, filed on Jul. 23, 1999, as a national stage application, under 35 U.S.C. .sctn.371, of international application PCT/US97/21463, filed Nov. 21, 1997, which claims the priority of the filing date of U.S. Provisional Application Serial No. 60/031,338, filed Nov. 21, 1996.

```
=> d his

     (FILE 'HOME' ENTERED AT 16:31:08 ON 16 OCT 2002)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 16:31:19 ON 16 OCT
     2002
L1             2 S PTTG-C
L2             0 S PITUITARY(W)TUMOR(5A)CARBOXY-TERMINAL
L3             0 S PTTG(W)CARBOXY-TERMINAL
L4             2 DUP REM L1 (0 DUPLICATES REMOVED)

=> d bib ab 1-2 l4

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2002 ACS
AN   2001:851202  CAPLUS
DN   136:4255
TI   C-terminal peptides of the PTTG gene product and their use in inhibition
     of neoplastic cellular proliferation or transformation
IN   Horwitz, Gregory A.; Zhang, Xun; HeaneyAnthony, P.; Melmed, Shlomo
PA   Cedars-Sinai Medical Center, USA
SO   PCT Int. Appl., 190 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 6
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2001087934      A2   20011122       WO 2001-US15254  20010512
     WO 2001087934      A3   20020530
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2002147162      A1   20021010       US 2001-777422   20010205
PRAI US 2000-569956     A    20000512
     US 2000-687911     A    20001013
     US 2000-730469     A    20001204
     US 2001-777422     A    20010205
     US 1996-31338P     P    19961121
     WO 1997-US21463    W    19971121
     US 1999-894251     A2   19990723
AB   A method of inhibiting neoplastic cellular proliferation and
     transformation of mammalian cells using C-terminal peptides derived from
     the product of the PTTG (pituitary tumor transforming gene) gene is
     described.  The peptides regulate the function of the protein and gene
     expression in a dominant neg. manner.  The peptides may be used directly,
     as fusion proteins with uptake-promoting peptides, or expression vectors
     encoding the peptides may be used in gene therapy.  The peptides may also
     increase the effectiveness of cytotoxic chemotherapeutic agents
     conventionally used to treat breast or ovarian cancers, thus allowing
     lower EDs of the agents to be administered.  Kits comprising the
inventive
     compns. are also disclosed for the treatment of neoplastic cellular
     proliferation in vitro or in vivo.  Isolated PTTG-C
     peptides and PTTG-C-related polynucleotides are also
```

disclosed, as are anti-**PTTG**-**C**-specific antibodies.
Cloning and characterization of the PTTG gene and its role in neoplastic transformation is described. Two-hybrid assays showed that the PTTG gene product acted as a transcriptional activator. Deletion anal. identified the C-terminal region as important in regulating neoplastic transformation. This area is proline-rich and includes an SH3 domain.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 2001:850858 CAPLUS
DN 136:4254
TI Pituitary tumor transforming gene 2 (PTTG2) and its role in the regulation
of expression of pituitary tumor transforming gene 1
IN Prezant, Toni Rita; Heaney, Anthony P.; Melmed, Shlomo
PA Cedars-Sinai Medical Center, USA
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087039	A2	20011122	WO 2001-US15255	20010512
	WO 2001087039	A3	20020321		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002147162	A1	20021010	US 2001-777422	20010205
	AU 2001063059	A5	20011126	AU 2001-63059	20010512
PRAI	US 2000-730469	A	20000120		
	US 2000-569956	A	20000512		
	US 2000-687911	A	20001013		
	US 2001-777422	A	20010205		
	US 1996-31338P	P	19961121		
	WO 1997-US21463	W	19971121		
	US 1999-894251	A2	19990723		
	WO 2001-US15255	W	20010512		

AB Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves
the use of pituitary tumor transforming gene 2 (PTTG2) product, which has the ability to regulate endogenous PTTG1 expression in a dominant neg. manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG2-encoding polynucleotides to mammalian cells,
whether in vitro or in vivo, to inhibit the endogenous expression of PTTG1. Other embodiments are directed to peptide-based treatments that deliver PTTG2 peptide mols. to the cells, which inhibit endogenous PTTG1 expression and/or PTTG1 function. Kits useful in practicing the inventive
method are also disclosed.